A citation-based method for searching scientific literature

Cecelia A Bellcross. Curr Probl Cancer 2014
Times Cited: 1







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium.
D Ford, D F Easton, M Stratton, S Narod, D Goldgar, P Devilee, D T Bishop, B Weber, G Lenoir, J Chang-Claude,[...]. Am J Hum Genet 1998
100

Genetic susceptibility to breast cancer.
Angela R Bradbury, Olufunmilayo I Olopade. Rev Endocr Metab Disord 2007
53
100

Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.
Bella Kaufman, Ronnie Shapira-Frommer, Rita K Schmutzler, M William Audeh, Michael Friedlander, Judith Balmaña, Gillian Mitchell, Georgeta Fried, Salomon M Stemmer, Ayala Hubert,[...]. J Clin Oncol 2015
975
100



Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE.
Nasim Mavaddat, Susan Peock, Debra Frost, Steve Ellis, Radka Platte, Elena Fineberg, D Gareth Evans, Louise Izatt, Rosalind A Eeles, Julian Adlard,[...]. J Natl Cancer Inst 2013
482
100

The Angelina Jolie effect: how high celebrity profile can have a major impact on provision of cancer related services.
D Gareth Evans, Julian Barwell, Diana M Eccles, Amanda Collins, Louise Izatt, Chris Jacobs, Alan Donaldson, Angela F Brady, Andrew Cuthbert, Rachel Harrison,[...]. Breast Cancer Res 2014
178
100

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.
M William Audeh, James Carmichael, Richard T Penson, Michael Friedlander, Bethan Powell, Katherine M Bell-McGuinn, Clare Scott, Jeffrey N Weitzel, Ana Oaknin, Niklas Loman,[...]. Lancet 2010
932
100

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.
Peter C Fong, David S Boss, Timothy A Yap, Andrew Tutt, Peijun Wu, Marja Mergui-Roelvink, Peter Mortimer, Helen Swaisland, Alan Lau, Mark J O'Connor,[...]. N Engl J Med 2009
100

Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients.
Marc D Schwartz, Caryn Lerman, Barbara Brogan, Beth N Peshkin, Chanita Hughes Halbert, Tiffani DeMarco, William Lawrence, David Main, Clinton Finch, Colette Magnant,[...]. J Clin Oncol 2004
189
100


ENIGMA--evidence-based network for the interpretation of germline mutant alleles: an international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genes.
Amanda B Spurdle, Sue Healey, Andrew Devereau, Frans B L Hogervorst, Alvaro N A Monteiro, Katherine L Nathanson, Paolo Radice, Dominique Stoppa-Lyonnet, Sean Tavtigian, Barbara Wappenschmidt,[...]. Hum Mutat 2012
181
100

Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer.
Anne-Renee Hartman, Rajesh R Kaldate, Lisa M Sailer, Lisa Painter, Charles E Grier, Robbin R Endsley, Marlena Griffin, Stephanie A Hamilton, Cynthia A Frye, Mark A Silberman,[...]. Cancer 2012
120
100

TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer.
Steven J Isakoff, Erica L Mayer, Lei He, Tiffany A Traina, Lisa A Carey, Karen J Krag, Hope S Rugo, Minetta C Liu, Vered Stearns, Steven E Come,[...]. J Clin Oncol 2015
226
100

Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.
Susan M Domchek, Tara M Friebel, Christian F Singer, D Gareth Evans, Henry T Lynch, Claudine Isaacs, Judy E Garber, Susan L Neuhausen, Ellen Matloff, Rosalind Eeles,[...]. JAMA 2010
824
100

Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2.
Kathleen E Malone, Colin B Begg, Robert W Haile, Ake Borg, Patrick Concannon, Lina Tellhed, Shanyan Xue, Sharon Teraoka, Leslie Bernstein, Marinela Capanu,[...]. J Clin Oncol 2010
112
100

A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1.
Y Miki, J Swensen, D Shattuck-Eidens, P A Futreal, K Harshman, S Tavtigian, Q Liu, C Cochran, L M Bennett, W Ding. Science 1994
100

Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer.
Fergus J Couch, Steven N Hart, Priyanka Sharma, Amanda Ewart Toland, Xianshu Wang, Penelope Miron, Janet E Olson, Andrew K Godwin, V Shane Pankratz, Curtis Olswold,[...]. J Clin Oncol 2015
355
100

Identification of a new complex deleterious mutation in exon 18 of the BRCA2 gene in a hereditary male/female breast cancer family.
Orland Diez, Sara Gutiérrez-Enríquez, Miriam Masas, Anna Tenés, Carme Yagüe, Angels Arcusa, Gemma Llort. Breast Cancer Res Treat 2010
2
100

Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.
Timothy R Rebbeck, Tara Friebel, Henry T Lynch, Susan L Neuhausen, Laura van 't Veer, Judy E Garber, Gareth R Evans, Steven A Narod, Claudine Isaacs, Ellen Matloff,[...]. J Clin Oncol 2004
695
100

BRCA in breast cancer: ESMO Clinical Practice Guidelines.
J Balmaña, O Díez, I T Rubio, F Cardoso. Ann Oncol 2011
114
100

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.
Jonathan Ledermann, Philipp Harter, Charlie Gourley, Michael Friedlander, Ignace Vergote, Gordon Rustin, Clare L Scott, Werner Meier, Ronnie Shapira-Frommer, Tamar Safra,[...]. Lancet Oncol 2014
841
100

Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.
Noah D Kauff, Jaya M Satagopan, Mark E Robson, Lauren Scheuer, Martee Hensley, Clifford A Hudis, Nathan A Ellis, Jeff Boyd, Patrick I Borgen, Richard R Barakat,[...]. N Engl J Med 2002
861
100

Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105.
Melinda L Telli, Kristin C Jensen, Shaveta Vinayak, Allison W Kurian, Jafi A Lipson, Patrick J Flaherty, Kirsten Timms, Victor Abkevich, Elizabeth A Schackmann, Irene L Wapnir,[...]. J Clin Oncol 2015
137
100

Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions.
Johnathan M Lancaster, C Bethan Powell, Lee-May Chen, Debra L Richardson. Gynecol Oncol 2015
154
100

The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds.
S V Tavtigian, J Simard, J Rommens, F Couch, D Shattuck-Eidens, S Neuhausen, S Merajver, S Thorlacius, K Offit, D Stoppa-Lyonnet,[...]. Nat Genet 1996
661
100

BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group.
Kathryn Alsop, Sian Fereday, Cliff Meldrum, Anna deFazio, Catherine Emmanuel, Joshy George, Alexander Dobrovic, Michael J Birrer, Penelope M Webb, Colin Stewart,[...]. J Clin Oncol 2012
665
100

Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination.
Ellen Warner, Donald B Plewes, Kimberley A Hill, Petrina A Causer, Judit T Zubovits, Roberta A Jong, Margaret R Cutrara, Gerrit DeBoer, Martin J Yaffe, Sandra J Messner,[...]. JAMA 2004
755
100


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.